Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive Macaques.
Kannanganat S, Wyatt LS, Gangadhara S, Chamcha V, Chea LS, Kozlowski PA, LaBranche CC, Chennareddi L, Lawson B, Reddy PB, Styles TM, Vanderford TH, Montefiori DC, Moss B, Robinson HL, Amara RR. Kannanganat S, et al. Among authors: wyatt ls. J Immunol. 2016 Nov 1;197(9):3586-3596. doi: 10.4049/jimmunol.1600629. Epub 2016 Sep 28. J Immunol. 2016. PMID: 27683750 Free PMC article.
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine.
Amara RR, Smith JM, Staprans SI, Montefiori DC, Villinger F, Altman JD, O'Neil SP, Kozyr NL, Xu Y, Wyatt LS, Earl PL, Herndon JG, McNicholl JM, McClure HM, Moss B, Robinson HL. Amara RR, et al. Among authors: wyatt ls. J Virol. 2002 Jun;76(12):6138-46. doi: 10.1128/jvi.76.12.6138-6146.2002. J Virol. 2002. PMID: 12021347 Free PMC article.
Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.
Amara RR, Villinger F, Staprans SI, Altman JD, Montefiori DC, Kozyr NL, Xu Y, Wyatt LS, Earl PL, Herndon JG, McClure HM, Moss B, Robinson HL. Amara RR, et al. Among authors: wyatt ls. J Virol. 2002 Aug;76(15):7625-31. doi: 10.1128/jvi.76.15.7625-7631.2002. J Virol. 2002. PMID: 12097576 Free PMC article.
Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.
Earl PL, Americo JL, Wyatt LS, Eller LA, Montefiori DC, Byrum R, Piatak M, Lifson JD, Amara RR, Robinson HL, Huggins JW, Moss B. Earl PL, et al. Among authors: wyatt ls. Virology. 2007 Sep 15;366(1):84-97. doi: 10.1016/j.virol.2007.02.041. Epub 2007 May 11. Virology. 2007. PMID: 17499326 Free PMC article.
GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine.
Lai L, Vödrös D, Kozlowski PA, Montefiori DC, Wilson RL, Akerstrom VL, Chennareddi L, Yu T, Kannanganat S, Ofielu L, Villinger F, Wyatt LS, Moss B, Amara RR, Robinson HL. Lai L, et al. Among authors: wyatt ls. Virology. 2007 Dec 5;369(1):153-67. doi: 10.1016/j.virol.2007.07.017. Epub 2007 Aug 14. Virology. 2007. PMID: 17698160 Free PMC article.
HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X, Basu R, Sawant S, Beaumont D, Kwa SF, LaBranche C, Seaton KE, Yates NL, Montefiori DC, Ferrari G, Wyatt LS, Moss B, Alam SM, Haynes BF, Tomaras GD, Robinson HL. Shen X, et al. Among authors: wyatt ls. J Virol. 2017 Nov 30;91(24):e01077-17. doi: 10.1128/JVI.01077-17. Print 2017 Dec 15. J Virol. 2017. PMID: 29021394 Free PMC article.
101 results